Compare SWAG & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWAG | EVAX |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 31.9M |
| IPO Year | N/A | 2020 |
| Metric | SWAG | EVAX |
|---|---|---|
| Price | $1.70 | $3.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 30.7K | ★ 32.1K |
| Earning Date | 03-27-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $1.20 |
| 52 Week High | $3.50 | $12.15 |
| Indicator | SWAG | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 49.34 |
| Support Level | $1.64 | $2.45 |
| Resistance Level | $1.89 | $4.64 |
| Average True Range (ATR) | 0.11 | 0.40 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 44.83 | 38.48 |
Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, it offers its clients custom sourcing capabilities, which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, event assets, order and inventory management, and designing and hosting online retail pop-up shops. The company's segment consists of the Stran segment and the SLS segment. The company generates the majority of its revenue from the Stran segment.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.